Fortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)
Stock Information for Avenue Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.